Advanced Biomed Inc.
ADVB evidence brief
What we can confirm
- Market Cap:
- $10.8M
What it means
What to watch
Prepared research question
What matters most for ADVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADVB
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based products for precision oncology, including early cancer screening and circulating tumor cell detection, and has recently launched its A+PerfusC system.
Key risk: No revenue and ongoing losses
Market Cap
$10.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based products for precision oncology, including early cancer screening and circulating tumor cell detection, and has recently launched its A+PerfusC system.
- Advanced Biomed has not yet generated any revenue from product sales and expects to remain in a state of continuous loss for the next two to three years [sec_mda · as of 2026-05-15].
- For the nine-month period ended March 31, 2026, the company reported net income of $5,982 thousand, compared to a net loss of $2,557 thousand for the same period in 2025 [sec_mda · as of 2026-05-15].
- As of March 31, 2026, the company had working capital surplus of $9,101 thousand and shareholders' equity of $9.2M [sec_mda · as of 2026-05-15] [latest reported financials].
- The company launched the A+PerfusC system in September 2025, designed to replicate human physiological conditions in vitro [news · published 2025-09-19].
- Advanced Biomed sold its Hong Kong subsidiary in December 2025 for US$23,000 [sec_mda · as of 2026-05-15].
What works
- The company has a working capital surplus of $9,101 thousand as of March 31, 2026, indicating near-term liquidity [sec_mda · as of 2026-05-15].
- Advanced Biomed has developed a portfolio of oncology-focused products, including the A+LCGuard lung cancer early screening kit and the A+PerfusC system, targeting precision medicine and advanced diagnostics [sec_mda · as of 2026-05-15] [news · published 2025-09-19].
- The company reported a positive net income of $5,982 thousand for the nine-month period ended March 31, 2026, compared to a loss in the prior period [sec_mda · as of 2026-05-15].
What to weigh
- Advanced Biomed has never generated revenue from product sales and does not expect to do so until it completes clinical development and obtains regulatory approvals, which may never occur [sec_mda · as of 2026-05-15].
- The company expects to remain in a state of continuous loss for the next two to three years [sec_mda · as of 2026-05-15].
- The sale of its Hong Kong subsidiary for only US$23,000 in December 2025 may indicate limited value from that asset [sec_mda · as of 2026-05-15].
- The A+LCGuard kit is a Class III medical device requiring clinical trials for registration, and the company acknowledges that regulatory approval timelines are uncertain [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
No revenue from product sales to date
“generated any revenue from the sale of products, and we do not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.”
SEC MD&A · May 15, 2026
Positive net income for nine-month period ended March 31, 2026
“For the nine-month periods ended March 31, 2026 and 2025, the Company reported net income (loss) of 5,982 thousand and (2,557) thousand, respectively.”
SEC MD&A · May 15, 2026
Working capital surplus as of March 31, 2026
“As of March 31, 2026 and June 30, 2025, the Company's working capital surplus was $9,101 thousand and $3,143 thousand, respectively.”
SEC MD&A · May 15, 2026
Launch of A+PerfusC system
“Advanced Biomed Launches A+PerfusC System Designed To Replicate Human Physiological Conditions In Vitro”
News · September 19, 2025
Risks & what to watch (3)›
Key risks
- No revenue and ongoing losses — Company has never generated product revenue and expects continuous losses for 2-3 years [sec_mda · as of 2026-05-15].
- Regulatory approval uncertainty — Class III device A+LCGuard requires clinical trials; approval timeline is uncertain [sec_mda · as of 2026-05-15].
- Going concern dependency — Company's viability depends on developing, registering, and obtaining regulatory approval for products [sec_mda · as of 2026-05-15].
What to watch
- Progress of clinical trials for the A+LCGuard lung cancer early screening kit [sec_mda · as of 2026-05-15].
- Any new revenue streams or partnership announcements following the A+PerfusC launch [news · published 2025-09-19].
- Changes in working capital and cash runway as the company continues R&D without product revenue [sec_mda · as of 2026-05-15].
Sources: Competitor trials · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Advanced Biomed Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Advanced Biomed Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 1.3%
- Days to cover
- 0.0
- Shares short
- 13,424
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Advanced Biomed Inc.?
Advanced Biomed Inc. (ADVB) is a pre-revenue biotechnology company developing microfluidic biochip-based products for precision oncology, including early cancer screening and circulating tumor cell detection, and has recently launched its A+PerfusC system.
Who is the CEO of Advanced Biomed Inc.?
Mr. Xiaomin Chen Ph.D. is the chief executive officer of Advanced Biomed Inc. (ADVB).
Where is Advanced Biomed Inc. headquartered?
Advanced Biomed Inc. (ADVB) is headquartered in New York, NY, United States.
What therapeutic areas does Advanced Biomed Inc. focus on?
Advanced Biomed Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.